United StatesBiotech & Genomic Medicine▲
Truist Sees Positive Readthrough for Maze After Vertex Kidney Data
Truist analyst Danielle Brill identified a significant positive readthrough for Maze Therapeutics following positive Phase 2 topline data from Vertex Pharmaceuticals, validating APOL1 inhibition in classic APOL1-mediated kidney disease and supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target on Maze, noting the market is large enough to support blockbuster potential for Maze's MZE829 even if efficacy merely matches Vertex's inaxaplin. Maze reported $494.9 million in cash, cash equivalents, and marketable securities in Q2 2026, funding its Phase 2 HORIZON trial of MZE829 with cohort updates expected in late 2026 or early 2027 and a pivotal trial planned for H1 2027. Vertex, which posted $3.33 billion in Q2 2026 revenue, up 12% year-over-year, and holds $13.6 billion in cash and marketable securities, raised its full-year 2026 revenue guidance to $13.1–$13.2 billion. Maze faces late-mover risk behind inaxaplin and reported a Q2 2026 net loss of $44.7 million, while Vertex's R&D and SG&A expenses reached $1.6 billion in Q2 2026.
About megatrends
Biotech & Genomic Medicine › Rare Disease ▲Demand
MAZE · Technology · Positive Vertex's positive Phase 2 APOL1 kidney data validates APOL1 inhibition and supports a large addressable population, a positive readthrough for Maze's MZE829.
MAZE · Capital · Positive Truist reiterated a Buy rating and $64 price target on Maze, citing blockbuster potential for MZE829.
VRTX · Technology · Positive Vertex's inaxaplin posted positive Phase 2 topline data in classic APOL1-mediated kidney disease, validating the mechanism.
VRTX · Capital · Positive Vertex posted Q2 2026 revenue up 12% YoY and raised full-year 2026 revenue guidance to $13.1–$13.2 billion.